Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. - Wikidata - awgldk - TriplyDB

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

http://www.wikidata.org/entity/Q30229074

about

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.Production of adenovirus vectors and their use as a delivery system for influenza vaccines.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.A highly immunogenic vaccine against A/H7N9 influenza virus A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.Viral vector-based influenza vaccines.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses.Adenoviral vector immunity: its implications and circumvention strategies.A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.A novel cardiotropic murine adenovirus representing a distinct species of mastadenoviruses.Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.Strategies to overcome host immunity to adenovirus vectors in vaccine development.An update on canine adenovirus type 2 and its vectors.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Progress on adenovirus-vectored universal influenza vaccines.155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication.A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.Non-replicating adenovirus vectors expressing avian influenza virus hemagglutinin and nucleocapsid proteins induce chicken specific effector, memory and effector memory CD8(+) T lymphocytes.A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose

P2860

Q21134724-6AFED7A9-F87A-430E-B5BD-0A2B4ADDF24C Q24597625-97E8B5EF-441E-4919-B18A-21ADE62137F6 Q27013568-2DC32549-C91A-4FEB-86A9-F3FB0494D63C Q30223058-3FD4AE39-05CB-4ADA-B686-8B6BB7CE4F74 Q30226988-CBEC81C3-2C8A-4387-BF65-F52A47E0CF0E Q30227194-1A700CCA-3B1F-43F1-ADCA-31BCAB66A502 Q30353770-52E97930-FCB4-4CFF-AF44-91E8917E371D Q30382097-2E580D37-D73D-4207-87A9-AECDD741154B Q30383516-63ED42B4-444F-40C6-BA34-417E8EF8F9E9 Q30389068-1E5D5838-380A-46BB-BD7F-56C60C99B3A9 Q30390938-3E343F0D-AAEA-4266-975C-84E607E406E0 Q30427591-054F5CF7-5E8D-473F-AD25-CD8424F8B30B Q33490614-00BE9A9B-D15C-4F86-A260-BB1E479CC77D Q33565630-8C8B631D-9702-44F1-8D40-33B344A5D588 Q33778607-D07F80B2-49F3-45E9-A654-EB72ABBE94E7 Q33848838-7BECC733-33DD-4159-87D0-CC3514131CA7 Q34153735-2B3D563E-8ACE-4ABF-B435-7D48B5575452 Q34178208-225CDB08-1FED-4F30-81FB-073D087C0906 Q35672866-C7BF76FD-18DE-471F-B95F-9619C15F40EB Q36456552-A3BB98EC-3FC4-4478-8D39-15C638CBB7F1 Q36759754-876D204C-467E-4708-8AF9-54120F697866 Q37191886-E5390C09-9229-4654-9D15-F27FB5976357 Q37309252-63F26EA0-96AC-49C4-A07F-8E2D3617AA7A Q37349242-7B23674E-E19C-4466-B047-743C56645A98 Q37503253-DB1D6FA5-EFE3-4729-B433-F3DA00351BE7 Q37945220-02BD1A77-776B-446F-8C27-3B07E5DB4209 Q38284700-D4F16E34-A153-411E-B51F-EEE5074A3B1D Q38421971-8E46E345-36B9-489C-8427-4409D513A044 Q38721445-9775A3D5-116D-49B0-B270-C80F6E9BAC65 Q40379142-83AF7CEB-0AF9-40DF-8A02-DD671868F2DF Q42451182-F2C895F2-7B7D-4554-AB78-47244BB52B92 Q56901675-21061FC7-49B2-4E6D-A6D9-F764DD4520C3

P2860

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

http://www.wikidata.org/entity/Q30229074

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bovine adenoviral vector-based ...... nity against human adenovirus.

@ast

Bovine adenoviral vector-based ...... nity against human adenovirus.

@en

type

label

Bovine adenoviral vector-based ...... nity against human adenovirus.

@ast

Bovine adenoviral vector-based ...... nity against human adenovirus.

@en

prefLabel

Bovine adenoviral vector-based ...... nity against human adenovirus.

@ast

Bovine adenoviral vector-based ...... nity against human adenovirus.

@en

P1433

Q30229074-643DFE4E-17FB-4DDA-AA45-0EE5921FE604

P1476

Q30229074-1454DC32-A490-4301-8CE7-F99306EB4CAB

P2093

Q30229074-46B35EC9-D7AF-4934-BC8C-4BAF7C146744

Q30229074-761D0128-DC89-4BEB-9457-5F8DBD084243

Q30229074-E3F959A4-8E79-4091-965A-E67EDD773F84

P2860

Q30229074-059EC9E2-4164-41AB-8C06-582CAAF2A56A

Q30229074-0800EB3B-B564-42A6-8AD3-19609A5D132F

Q30229074-0AAAA493-5C3C-4AC1-8687-321CF03B9675

Q30229074-16BEBB2E-5E93-4D47-8BBA-16BA3A9E7DA9

Q30229074-1B18B96D-F504-4CEB-A675-0D2F1E3F0DE1

Q30229074-23429369-22A6-4346-AA21-4FD8B2AE390C

Q30229074-2EA84CA9-3447-45AB-8B8D-648345CD0BAC

Q30229074-353D7A92-35FE-42B1-B920-87DEC74273CC

Q30229074-3D4DECED-6FD6-4F62-ACAF-E0AF09E30BCC

Q30229074-4188D235-563F-4272-AD50-7F783E2E5584

P304

Q30229074-29E87C40-0527-4BA4-A390-3CE1ACED35FF

P31

Q30229074-8E493842-2889-4A4F-B2F3-8C88C13ED752

P356

Q30229074-22173528-FB4A-43B8-A59B-B7DA8BC180D3

P433

Q30229074-ABA6CE95-B241-4D04-B043-A609F255BADE

P478

Q30229074-6DBAEB7B-FD3A-4808-BD68-099C7009D04B

P50

Q30229074-EBE7E2DB-FAA4-47C2-AD5E-833B79F9D0F5

P577

Q30229074-3F2D5216-061B-42E3-97A5-E428F1AA6040

P5875

Q30229074-1ABC92DA-EE1C-4D39-851A-C45A28CA79C6

P698

Q30229074-6A22DB94-C0EB-40BB-862E-8E3062B0ECAF

P921

Q30229074-C970D625-ADC6-46B2-9B13-9621E5ADF7EC

P932

Q30229074-0B637DED-34C4-4278-8001-40CFAC87F278

P356

P1433

Molecular Therapy

P1476

Bovine adenoviral vector-based ...... nity against human adenovirus.

@en

P2093

Aseem Pandey

http://www.w3.org/2001/XMLSchema#string

Neetu Singh

http://www.w3.org/2001/XMLSchema#string

Suresh K Mittal

http://www.w3.org/2001/XMLSchema#string

P2860

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

Characteristics of a human cell line transformed by DNA from human adenovirus type 5

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans.

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Cell-mediated protection in influenza infection.

Scientific barriers to developing vaccines against avian influenza viruses.

Avian influenza virus (H5N1): a threat to human health.

Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

P304

965-971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.12

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Lakshmi Jayashankar

P577

2008-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5551781

http://www.w3.org/2001/XMLSchema#string

P698

18301400

http://www.w3.org/2001/XMLSchema#string

P921

P932

2700267

http://www.w3.org/2001/XMLSchema#string